Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population.

Stefano MolicaTait D ShanafeltDavid John AllsupDiana Giannarelli

Published in: American journal of hematology (2023)

Pooled analysis of six mature phase 3 trials (RESONATE2, ILLUMINATE, ALLIANCE041202, ELEVATE-TN, CLL14, and GLOW) evaluating Bruton's tyrosine kinase inhibitors (BTKis) and venetoclax-based treatments suggests that these agents have reduced but not completely eliminated the overall survival (OS) gap between elderly chronic lymphocytic leukemia (CLL) patients and the age and sex-matched general population (AGMGP).

Keyphrases

chronic lymphocytic leukemia
end stage renal disease
ejection fraction
prognostic factors
drug delivery
community dwelling